Coherus Oncology (CHRS) Equity Average (2014 - 2026)

Coherus Oncology has disclosed Equity Average across 13 years of filings, most recently posting $69.8 million for Q1 2026.

• Equity Average for Q1 2026 came in at $69.8 million, up 144.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.8 million (up 144.26% YoY), and the FY2025 annual result was -$35.5 million, up 78.19% from the prior year.
• Equity Average came in at $69.8 million for Q1 2026 at Coherus Oncology, down from $74.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $103.8 million in Q3 2025 to a low of -$185.6 million in Q2 2023.
• The 5-year median for Equity Average is -$86.0 million (2024), against an average of -$68.0 million.
• Across the five-year window, Equity Average slumped 3588.37% in 2023 and jumped 220.64% in 2025, its largest moves.
• Coherus Oncology's Equity Average stood at -$117.3 million in 2022, then plunged by 39.43% to -$163.5 million in 2023, then jumped by 32.74% to -$110.0 million in 2024, then surged by 167.64% to $74.4 million in 2025, then decreased by 6.15% to $69.8 million in 2026.
• The last three Equity Average figures came in at $69.8 million (Q1 2026), $74.4 million (Q4 2025), and $103.8 million (Q3 2025), per Business Quant data.